Figure 1From: Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study Serum trough infliximab levels during the infusioncycle in antibody-forming and non-anti-body forming RA patients.Back to article page